Trump Administration’s Partial Medical Cannabis Rescheduling Sparks Confusion
The Trump administration has initiated a partial medical cannabis rescheduling, moving specific cannabis products from Schedule I to Schedule III under federal law. This move, while signaling a shift in federal policy, has introduced considerable ambiguity for the industry, as reported by the Guardian on April 30, 2026. Acting Attorney General Todd Blanche signed an order last week that specifically targets products sold under state medical cannabis licenses and those approved by the Food and Drug Administration (FDA).
As previously reported by Hemp Gazette, the administration had indicated an intent to reclassify cannabis. However, this recent order is not a broad rescheduling of cannabis itself, but a more nuanced adjustment that has left many stakeholders seeking clarity on its practical implications.
The Scope of Partial Medical Cannabis Rescheduling
The order signed by Acting Attorney General Todd Blanche reclassifies certain cannabis-related products from Schedule I, defined as substances with no accepted medical use, to Schedule III. This category includes legally regulated substances such as certain formulations of Tylenol with codeine and ketamine. The reclassification applies to:
- Products sold under state medical cannabis licenses.
- FDA-approved cannabis products.
Cat Packer, director of drug markets and legal regulation at the Drug Policy Alliance, emphasized that this is a “partial rescheduling, at best,” and not a broad reclassification of marijuana. Packer noted that the “FDA-approved” component of the order primarily pertains to prospective FDA-approved products that do not yet exist, rather than affecting the limited number of cannabis-related pharmaceuticals already approved by the FDA.
Regulatory Ambiguities and Treaty Obligations
A key concern highlighted by Packer is that the order appears to “predetermine the scheduling outcome for future FDA-approved drugs containing marijuana without a full, evidence-based risk evaluation.” The administration justifies this partial move by repeatedly referencing the Single Convention on Narcotic Drugs, a 1961 United Nations treaty signed by 73 nations, including the United States. This convention mandates that specified “narcotics,” including cannabis, be produced only in limited quantities for scientific and medical purposes.
This reliance on the Single Convention has reignited an ongoing debate regarding the US’s alignment with the treaty, especially given the federal government’s stance on state-level legalization. Countries like Canada, despite their participation in the Single Convention, have implemented regulated cannabis markets, demonstrating varying interpretations of treaty obligations.
Industry Reaction and Operational Challenges
The announcement has elicited a mixed response from the cannabis industry, characterized by both confusion and cautious optimism. Ryan Hunter, Chief Revenue Officer at Colorado-based Spherex Labs, described the announcement as “very silly,” stating that it has only complicated an already intricate regulatory landscape. Alex Gonzalez, co-founder and president of Calyx Containers, a cannabis packaging company, suggested the timing of the announcement might be strategic, potentially aimed at influencing voter sentiment ahead of midterms.
Operationally, the order creates a bifurcation that poses challenges for businesses. Hunter explained that for dual-licensed dispensaries, which sell both medical and adult-use cannabis, the products themselves are often identical in composition and cost, yet they are now treated differently from a federal legal perspective based solely on the purchasing pathway.
Equity and Patient Protections
Despite the federal recognition of medical cannabis products as legitimate medicine, Cat Packer raised concerns about the practical realization of these protections. Medical cannabis patients, for instance, may still face discrimination in housing and employment. Furthermore, the order’s exclusive focus on medical cannabis providers registering with the DEA could disproportionately affect Black and Latino cannabis entrepreneurs. These groups are often more likely to hold adult-use licenses due to the high barriers to entry in early medical markets, while equity programs have largely advanced through adult-use legalization initiatives.
Future Outlook for Medical Cannabis Rescheduling
While the partial rescheduling is seen by some as a positive, albeit confusing, signal from a high level of government, the path to broader reform remains uncertain. Acting Attorney General Blanche announced that the DEA will conduct a new administrative hearing for rescheduling on June 29. However, Packer cautioned that full rescheduling of cannabis is “far from certain,” and even if it occurs, it would still fall short of the majority of Americans’ support for full legalization.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
